Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Redeye Theme: Fight Cancer 2024
13 slides from Expres2ion Biotech Holding Ab's conference presentation, Jan 24, 2024
Slide 1: Innovative Vaccines for a healthier world
Redeye Theme: FIGHT CANCER January 24, 2024, Stockholm Innovative Vaccines for a healthier world Hosted by
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: ExpreS2 platform
ExpreS2 platform We create the antigen, so the body creates the antibody to fight infection What it does Produce …to create Simplified Vaccine How it adds Competitive Potential antigens… vaccines value advantages enhancements in These • The vaccine • Production speed • Modification of proprietary an
Slide 4: Delivery vehicles: Why we use virus-like particles (VLPs)
Delivery vehicles Why we use virus-like particles (VLPs) VLP ExpreS2-produced antigens have Replicating Killed been combined with multiple delivery viral whole vehicles and used on their own vectors virus Live attenuated Immunogenicity virus Soluble Replication- mRNA proteins VLPs are virus-derived
Slide 5: ExpreS2 platform: Phase III validated
ExpreS2 platform Phase III validated Stage Vaccine projects Discovery MucoVax influenza VICI Nipah Undisclosed Lead optimization ES2B-I002 cytomegalovirus INDIGO influenza CTA-enabling ES2B-C001 HER2 breast cancer + numerous additional Phase I 3 x Oxford University Malaria pharmaceutical and biotech
Slide 6: Vaccine Pipeline
Vaccine Pipeline CTA- Thematic area Program Indication Discovery Lead opt Ph 1 Ph 2 Ph 3 enabling HER2+ ES2B-C001 breast cancer Tox studies and manufacturing Oncology (therapeutic) Cytomegalovirus ES2B-I002 Lead opt. Infectious disease (prevention) Exploratory Undisclosed Disco. Undisclosed Innovati
Slide 7: Breast Cancer
BREAST BREAST CANCER CANCER The most common cancer 1 in 8 women will be diagnosed with invasive breast cancer in her lifetime of breast cancer tumors, HER2 ~25% is overexpressed, which is associated with a more aggressive disease, higher recurrence rate, and increased mortality1 685,000 deaths world
Slide 8: A therapeutic vaccine for HER2-expressing breast cancer to overcome drawbacks with current HER2 directed modalities
BREAST CANCER A therapeutic vaccine for HER2-expressing breast cancer to overcome drawbacks with current HER2 directed modalities Around 2 million new cases of breast cancer Monoclonal antibodies (mAbs), are the cornerstone of treatment for worldwide yearly HER2 pos breast cancer • Target an epitope
Slide 9: ES2B-C001 combines unique full-length antigen with highly immunogenic technology platform
BREAST CANCER ES2B-C001 combines unique full-length antigen with highly immunogenic technology platform leading to polyclonal antibody response HER2 protein • Highly immunogenic (all 4 extra-cellular A wide range of epitopes presented to B-cells. sub domains) Generate a strong polyclonal Ab response
Slide 10: PoC data for ES2B-C001 in mice
BREAST CANCER PoC data for ES2B-C001 in mice Vaccinations completely inhibited QD cells tumor growth in FVB mice, it was partially effective without adjuvant All n=10 Vehicle Control ES2B-C001 10 g i.m. ES2B-C001 10 g i.m.+Montanide Adjuvant bleeding vaccine administration 2.5 100 Tumor volume (cm
Slide 11: Promising preclinical data package
BREAST CANCER Promising preclinical data package • We have developed a promising HER2-VLP vaccine candidate to be tested in HER2 positive breast cancer patients, initially metastatic, then early cancer. • ES2B-C001 completely prevented tumor development after only 2 vaccinations in mice • The vaccin
Slide 12: Oncology Scientific Advisory Board
Oncology Scientific Advisory Board Dr. Giuseppe Curigliano, MD, PhD Dr. Ulrik Lassen, MD, PhD Associate Professor of Medical Oncology at the University of Milano and the Professor at University of Copenhagen, Department of Clinical Medicine. In Head of the Division of Early Drug Development at the E
Slide 13: Contact: Investor Relations
Contact: Investor Relations investor@expreS2ionbio.com Innovative vaccines for a healthier world 13
ExpreS2ion Biotech Holding — Redeye Theme: Fight Cancer 2024 on 6ix